<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37317297</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-2607</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>17</Day></PubDate></JournalIssue><Title>Microorganisms</Title><ISOAbbreviation>Microorganisms</ISOAbbreviation></Journal><ArticleTitle>The Fight against Poliovirus Is Not Over.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1323</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/microorganisms11051323</ELocationID><Abstract><AbstractText>Poliovirus (PV), the virus that causes both acute poliomyelitis and post-polio syndrome, is classified within the <i>Enterovirus C</i> species, and there are three wild PV serotypes: WPV1, WPV2 and WPV3. The launch of the Global Polio Eradication Initiative (GPEI) in 1988 eradicated two of the three serotypes of WPV (WPV2 and WPV3). However, the endemic transmission of WPV1 persists in Afghanistan and Pakistan in 2022. There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV). Between January 2021 and May 2023, a total of 2141 circulating VDPV (cVDPV) cases were reported in 36 countries worldwide. Because of this risk, inactivated poliovirus (IPV) is being used more widely, and attenuated PV2 has been removed from OPV formulations to obtain bivalent OPV (containing only types 1 and 3). In order to avoid the reversion of attenuated OPV strains, the new OPV, which is more stable due to genome-wide modifications, as well as sabin IPV and virus-like particle (VLP) vaccines, is being developed and offers promising solutions for eradicating WP1 and VDPV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mbani</LastName><ForeName>Chaldam Jespère</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie URL3610, Université de Lille, CHU Lille, 59000 Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratoire de Biologie Cellulaire et Moléculaire, Faculté des Sciences et Technique, Université Marien Ngouabi, Brazzaville BP 69, Congo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nekoua</LastName><ForeName>Magloire Pandoua</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-2981-0803</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie URL3610, Université de Lille, CHU Lille, 59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moukassa</LastName><ForeName>Donatien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Laboratoire de Biologie Cellulaire et Moléculaire, Faculté des Sciences et Technique, Université Marien Ngouabi, Brazzaville BP 69, Congo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hober</LastName><ForeName>Didier</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4301-2074</Identifier><AffiliationInfo><Affiliation>Laboratoire de Virologie URL3610, Université de Lille, CHU Lille, 59000 Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Microorganisms</MedlineTA><NlmUniqueID>101625893</NlmUniqueID><ISSNLinking>2076-2607</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">eradication</Keyword><Keyword MajorTopicYN="N">poliovirus</Keyword><Keyword MajorTopicYN="N">reversion</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword><Keyword MajorTopicYN="N">vaccine-derived poliovirus</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37317297</ArticleId><ArticleId IdType="pmc">PMC10220725</ArticleId><ArticleId IdType="doi">10.3390/microorganisms11051323</ArticleId><ArticleId IdType="pii">microorganisms11051323</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown B., Oberste M.S., Maher K., Pallansch M.A. Complete genomic sequencing shows that polioviruses and members of human enterovirus species C are closely related in the noncapsid coding region. J. Virol. 2003;77:8973–8984. doi: 10.1128/JVI.77.16.8973-8984.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.16.8973-8984.2003</ArticleId><ArticleId IdType="pmc">PMC167246</ArticleId><ArticleId IdType="pubmed">12885914</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 2018;16:368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch M.A., Roos R. Enteroviruses: Polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Knipe D.M., Howley P.M., editors. Fields Virology. Lippincott Williams and Wilkins; Philadelphia, PA, USA: 2007.</Citation></Reference><Reference><Citation>Nathanson N. The pathogenesis of poliomyelitis: What we don’t know. Adv. Virus. Res. 2008;71:1–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">18585526</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization.  [(accessed on 15 April 2023)];Weekly Epidemiological Record. 2022 97:277–300. Available online:  https://apps.who.int/iris/handle/10665/357167.</Citation></Reference><Reference><Citation>Davlantes E., Greene S.A., Tobolowsky F.A., Biya O., Wiesen E., Abebe F., Weldetsadik M.B., Eboh V.A., Chisema M.N., da Conceição Mário B., et al. Update on Wild Poliovirus Type 1 Outbreak-Southeastern Africa, 2021–2022. MMWR Morb. Mortal. Wkly Rep. 2023;72:391–397. doi: 10.15585/mmwr.mm7215a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7215a3</ArticleId><ArticleId IdType="pmc">PMC10121257</ArticleId><ArticleId IdType="pubmed">37053125</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F., Datta S.D., Quddus A., Vertefeuille J.F., Burns C.C., Jorba J., Wassilak S.G.F. Progress Toward Polio Eradication-Worldwide, January 2016–March 2018. MMWR Morb. Mortal. Wkly. Rep. 2018;67:524–528. doi: 10.15585/mmwr.mm6718a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6718a4</ArticleId><ArticleId IdType="pmc">PMC5944975</ArticleId><ArticleId IdType="pubmed">29746452</ArticleId></ArticleIdList></Reference><Reference><Citation>Agol V.I. Molecular mechanisms of poliovirus variation and evolution. Curr. Top. Microbiol. Immunol. 2006;299:211–259.</Citation><ArticleIdList><ArticleId IdType="pubmed">16568901</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J., Diop O.M., Iber J., Henderson E., Zhao K., Quddus A., Sutter R., Vertefeuille J.F., Wenger J., Wassilak S.G.F., et al. Update on Vaccine-Derived Poliovirus Outbreaks-Worldwide, January 2018–June 2019. MMWR Morb. Mortal. Wkly. Rep. 2019;68:1024–1028. doi: 10.15585/mmwr.mm6845a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6845a4</ArticleId><ArticleId IdType="pmc">PMC6855511</ArticleId><ArticleId IdType="pubmed">31725706</ArticleId></ArticleIdList></Reference><Reference><Citation>Blondel B., Autret A., Brisac C., Pelletier I., Martin-Latil S., Jegouic S., Bessaud M., Joffret M.L., Balanant J., Colbère-Garapin F., et al. Evolution génétique du poliovirus: Succès et difficultés de l’éradication de la poliomyélite paralytique [Genetic evolution of poliovirus: Success and difficulties in the eradication of paralytic poliomyelitis] Med. Trop. 2008;68:189–202.</Citation><ArticleIdList><ArticleId IdType="pubmed">18630055</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh M.T., Bujaki E., Dolan P.T., Smith M., Wahid R., Konz J., Weiner A.J., Bandyopadhyay A.S., Van Damme P., De Coster I., et al. Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020;27:736–751.e8. doi: 10.1016/j.chom.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras G., Dimock K., Furesz J., Gardell C., Hazlett D., Karpinski K., McCorkle G., Wu L. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. Biologicals. 1992;20:15–26. doi: 10.1016/S1045-1056(05)80003-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1045-1056(05)80003-X</ArticleId><ArticleId IdType="pubmed">1319179</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor P.D., Dunn G., Ramsay M.E., Brown D. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains. J. Med. Virol. 2005;75:153–160. doi: 10.1002/jmv.20250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20250</ArticleId><ArticleId IdType="pubmed">15543587</ArticleId></ArticleIdList></Reference><Reference><Citation>Macadam A.J., Ferguson G., Stone D.M., Meredith J., Knowlson S., Auda G., Almond J.W., Minor P.D. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: Relevance to poliomyelitis eradication. J. Virol. 2006;80:8653–8663. doi: 10.1128/JVI.00370-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00370-06</ArticleId><ArticleId IdType="pmc">PMC1563845</ArticleId><ArticleId IdType="pubmed">16912313</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 2005;59:587–635. doi: 10.1146/annurev.micro.58.030603.123625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.micro.58.030603.123625</ArticleId><ArticleId IdType="pubmed">16153180</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakoto-Andrianarivelo M., Jegouic S., Bessaud M., Delpeyroux F. Poliovirus et entérovirus C, même espèce, même “tribu” virale [Polioviruses and species C enteroviruses, viruses of the same species and “tribe”] Med. Sci. 2008;24:452–453.</Citation><ArticleIdList><ArticleId IdType="pubmed">18466715</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell R., Delwart E., Gorbalenya A.E., Hovi T., King A.M.Q., Knowles N.J., Lindberg A.M., Pallansch M.A., Palmenberg A.C., Reuter G., et al. Ictv Report Consortium: ICTV Virus Taxonomy Profile: Picornaviridae. J. Gen. Virol. 2017;98:2421–2422. doi: 10.1099/jgv.0.000911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000911</ArticleId><ArticleId IdType="pmc">PMC5725991</ArticleId><ArticleId IdType="pubmed">28884666</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo H., Li Y., Liu G., Jiang Y., Shen S., Bi R., Huang H., Cheng T., Wang C., Wei W. A second open reading frame in human enterovirus determines viral replication in intestinal epithelial cells. Nat. Commun. 2019;10:4066. doi: 10.1038/s41467-019-12040-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12040-9</ArticleId><ArticleId IdType="pmc">PMC6731315</ArticleId><ArticleId IdType="pubmed">31492846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lulla V., Dinan A.M., Hosmillo M., Chaudhry Y., Sherry L., Irigoyen N., Nayak K.M., Stonehouse N.J., Zilbauer M., Goodfellow I., et al. An upstream protein-coding region in enteroviruses modulates virus infection in gut epithelial cells. Nat. Microbiol. 2019;4:280–292. doi: 10.1038/s41564-018-0297-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-018-0297-1</ArticleId><ArticleId IdType="pmc">PMC6443042</ArticleId><ArticleId IdType="pubmed">30478287</ArticleId></ArticleIdList></Reference><Reference><Citation>Racaniello V.R. One hundred years of poliovirus pathogenesis. Virology. 2006;344:9–16. doi: 10.1016/j.virol.2005.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2005.09.015</ArticleId><ArticleId IdType="pubmed">16364730</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller S., Wimmer E., Cello J. Poliovirus and poliomyelitis: A tale of guts, brains, and an accidental event. Virus Res. 2005;11:175–193. doi: 10.1016/j.virusres.2005.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2005.04.008</ArticleId><ArticleId IdType="pubmed">15885840</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathanson N., Kew O.M. From emergence to eradication: The epidemiology of poliomyelitis deconstructed. Am. J. Epidemiol. 2010;172:1213–1229. doi: 10.1093/aje/kwq320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq320</ArticleId><ArticleId IdType="pmc">PMC2991634</ArticleId><ArticleId IdType="pubmed">20978089</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y., Mueller S., Chipman P.R., Bator C.M., Peng X., Bowman V.D., Mukhopadhyay S., Wimmer E., Kuhn R.J., Rossmann M.G. Complexes of poliovirus serotypes with their common cellular receptor, CD155. J. Virol. 2003;77:4827–4835. doi: 10.1128/JVI.77.8.4827-4835.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.8.4827-4835.2003</ArticleId><ArticleId IdType="pmc">PMC152153</ArticleId><ArticleId IdType="pubmed">12663789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan G., Freistadt M.S., Racaniello V.R. Neutralization of poliovirus by cell receptors expressed in insect cells. J. Virol. 1990;64:4697–4702. doi: 10.1128/jvi.64.10.4697-4702.1990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.64.10.4697-4702.1990</ArticleId><ArticleId IdType="pmc">PMC247955</ArticleId><ArticleId IdType="pubmed">2168959</ArticleId></ArticleIdList></Reference><Reference><Citation>Gómez Yafal A., Kaplan G., Racaniello V.R., Hogle J.M. Characterization of poliovirus conformational alteration mediated by soluble cell receptors. Virology. 1993;197:501–505. doi: 10.1006/viro.1993.1621.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1621</ArticleId><ArticleId IdType="pubmed">8212594</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodian D. Emerging concept of poliomyelitis infection. Science. 1955;122:105–108. doi: 10.1126/science.122.3159.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.122.3159.105</ArticleId><ArticleId IdType="pubmed">14385825</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin A.B. Pathogenesis of poliomyelitis; reappraisal in the light of new data. Science. 1956;123:1151–1157. doi: 10.1126/science.123.3209.1151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.123.3209.1151</ArticleId><ArticleId IdType="pubmed">13337331</ArticleId></ArticleIdList></Reference><Reference><Citation>Freistadt M.S., Fleit H.B., Wimmer E. Poliovirus receptor on human blood cells: A possible extraneural site of poliovirus replication. Virology. 1993;195:798–803. doi: 10.1006/viro.1993.1433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1433</ArticleId><ArticleId IdType="pubmed">8393247</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt H.V. Incubation of poliomyelitis as calculated from the time of entry into the central nervous system via the peripheral nerve pathways. Rev. Infect. Dis. 1990;12:547–556. doi: 10.1093/clinids/12.3.547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/12.3.547</ArticleId><ArticleId IdType="pubmed">2163095</ArticleId></ArticleIdList></Reference><Reference><Citation>Sartwell P.E. La période d’incubation de la poliomyélite. Am. J. St. Publique Nations Health. 1952;42:1403–1408. doi: 10.2105/AJPH.42.11.1403.</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.42.11.1403</ArticleId><ArticleId IdType="pmc">PMC1525998</ArticleId><ArticleId IdType="pubmed">12986020</ArticleId></ArticleIdList></Reference><Reference><Citation>Horstmann D.M., Paul J.R. The incubation period in human poliomyelitis and its implications. J. Am. Med. Assoc. 1947;135:11–14. doi: 10.1001/jama.1947.02890010013004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1947.02890010013004</ArticleId><ArticleId IdType="pubmed">20257743</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vries A.S., Harper J., Murray A., Lexau C., Bahta L., Christensen J., Cebelinski E., Fuller S., Kline S., Wallace G.S., et al. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N. Engl. J. Med. 2011;364:2316–2323. doi: 10.1056/NEJMoa1008677.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1008677</ArticleId><ArticleId IdType="pubmed">21675890</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R.W., Patriarca P.A., Suleiman A.J.M., Brogan S., Malankar P.G., Cochi S.L., Al-Ghassani A.A.K., El-Bualy M.S. Attributable risk of DTP (diphtheria and tetanus toxoids and pertussis vaccine) injection in provoking paralytic poliomyelitis during a large outbreak in Oman. J. Infect. Dis. 1992;165:444–449. doi: 10.1093/infdis/165.3.444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/165.3.444</ArticleId><ArticleId IdType="pubmed">1538150</ArticleId></ArticleIdList></Reference><Reference><Citation>Strebel P.M., Ion-Nedelcu N., Baughman A.L., Sutter R.W., Cochi S.L. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine--a risk factor for vaccine-associated paralytic poliomyelitis. N. Engl. J. Med. 1995;332:500–506. doi: 10.1056/NEJM199502233320804.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199502233320804</ArticleId><ArticleId IdType="pubmed">7830731</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin K.H., Lim Y.W. Post-poliomyelitis syndrome: Case report and review of the literature. Ann. Acad. Med. Singap. 2005;34:447–449.</Citation><ArticleIdList><ArticleId IdType="pubmed">16123820</ArticleId></ArticleIdList></Reference><Reference><Citation>Julien J., Leparc-Goffart I., Lina B., Fuchs F., Foray S., Janatova I., Aymard M., Kopecka H. Postpolio syndrome: Poliovirus persistence is involved in the pathogenesis. J. Neurol. 1999;246:472–476. doi: 10.1007/s004150050386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004150050386</ArticleId><ArticleId IdType="pubmed">10431774</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Hi Shing S., Chipika R.H., Finegan E., Murray D., Hardiman O., Bede P. Post-polio Syndrome: More Than Just a Lower Motor Neuron Disease. Front. Neurol. 2019;10:773. doi: 10.3389/fneur.2019.00773.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00773</ArticleId><ArticleId IdType="pmc">PMC6646725</ArticleId><ArticleId IdType="pubmed">31379723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaminski H.J., Tresser N., Hogan R.E., Martin E. Pathological analysis of spinal cords from survivors of poliomyelitis. Ann. N. Y. Acad. Sci. 1995;753:390–393. doi: 10.1111/j.1749-6632.1995.tb27569.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1995.tb27569.x</ArticleId><ArticleId IdType="pubmed">7611653</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharief M.K., Hentges R., Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. N. Engl. J. Med. 1991;325:749–755. doi: 10.1056/NEJM199109123251101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199109123251101</ArticleId><ArticleId IdType="pubmed">1651456</ArticleId></ArticleIdList></Reference><Reference><Citation>Bickerstaffe A., Beelen A., Lutter R., Nollet F. Elevated plasma inflammatory mediators in post-polio syndrome: No association with long-term functional decline. J. Neuroimmunol. 2015;289:162–167. doi: 10.1016/j.jneuroim.2015.10.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2015.10.019</ArticleId><ArticleId IdType="pubmed">26616886</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez H., Khademi M., Andersson M., Wallström E., Borg K., Olsson T. Prior poliomyelitis-evidence of cytokine production in the central nervous system. J. Neurol. Sci. 2002;205:9–13. doi: 10.1016/S0022-510X(02)00316-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(02)00316-7</ArticleId><ArticleId IdType="pubmed">12409177</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood D.J., Hull B. L20B cells simplify culture of polioviruses from clinical samples. J. Med. Virol. 1999;58:188–192. doi: 10.1002/(SICI)1096-9071(199906)58:2&lt;188::AID-JMV15&gt;3.0.CO;2-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(199906)58:2&lt;188::AID-JMV15&gt;3.0.CO;2-H</ArticleId><ArticleId IdType="pubmed">10335869</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerloff N., Sun H., Mandelbaum M., Maher C., Nix W.A., Zaidi S., Shaukat S., Seakamela L., Nalavade U.P., Sharma D.K., et al. Diagnostic Assay Development for Poliovirus Eradication. J. Clin. Microbiol. 2018;56:e01624-17. doi: 10.1128/JCM.01624-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01624-17</ArticleId><ArticleId IdType="pmc">PMC5786708</ArticleId><ArticleId IdType="pubmed">29212703</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Ling H., Yan D., Nishimura Y., Yoshida H., Wakita T., Shimizu H. Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) system for a highly sensitive detection of enterovirus in the stool samples of acute flaccid paralysis cases. BMC Infect. Dis. 2009;9:208. doi: 10.1186/1471-2334-9-208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-9-208</ArticleId><ArticleId IdType="pmc">PMC2803793</ArticleId><ArticleId IdType="pubmed">20015403</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington C., Sun H., Jeffries-Miles S., Gerloff N., Mandelbaum M., Pang H., Collins N., Burns C.C., Vega E. Culture-Independent Detection of Poliovirus in Stool Samples by Direct RNA Extraction. Microbiol. Spectr. 2021;9:e0066821. doi: 10.1128/Spectrum.00668-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/Spectrum.00668-21</ArticleId><ArticleId IdType="pmc">PMC8579935</ArticleId><ArticleId IdType="pubmed">34756088</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu W., Zhang Y. Isolation and Characterization of Vaccine-Derived Polioviruses, Relevance for the Global Polio Eradication Initiative. Methods Mol. Biol. 2016;1387:213–226.</Citation><ArticleIdList><ArticleId IdType="pubmed">26983736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpatrick D.R., Ching K., Iber J., Chen Q., Yang S.J., De L., Williams A.J., Mandelbaum M., Sun H., Oberste M.S., et al. Identification of vaccine-derived polioviruses using dual-stage real-time RT-PCR. J. Virol. Methods. 2014;197:25–28. doi: 10.1016/j.jviromet.2013.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2013.11.017</ArticleId><ArticleId IdType="pmc">PMC8215842</ArticleId><ArticleId IdType="pubmed">24321704</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpatrick D.R., Yang C.F., Ching K., Vincent A., Iber J., Campagnoli R., Mandelbaum M., De L., Yang S.J., Nix A., et al. Rapid group-, serotype-, and vaccine strain-specific identification of poliovirus isolates by real-time reverse transcription-PCR using degenerate primers and probes containing deoxyinosine residues. J. Clin. Microbiol. 2009;47:1939–1941. doi: 10.1128/JCM.00702-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.00702-09</ArticleId><ArticleId IdType="pmc">PMC2691077</ArticleId><ArticleId IdType="pubmed">19386844</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Avoort H.G., Hull B.P., Hovi T., Pallansch M.A., Kew O.M., Crainic R., Wood D.J., Mulders M.N., van Loon A.M. Comparative study of five methods for intratypic differentiation of polioviruses. J. Clin. Microbiol. 1995;33:2562–2566. doi: 10.1128/jcm.33.10.2562-2566.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jcm.33.10.2562-2566.1995</ArticleId><ArticleId IdType="pmc">PMC228529</ArticleId><ArticleId IdType="pubmed">8567883</ArticleId></ArticleIdList></Reference><Reference><Citation>Balanant J., Guillot S., Candrea A., Delpeyroux F., Crainic R. The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay. Virology. 1991;184:645–654. doi: 10.1016/0042-6822(91)90434-D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(91)90434-D</ArticleId><ArticleId IdType="pubmed">1679577</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . Polio Laboratory Manual. 4th ed. World Health Organization; Geneva, Switzerland: 2004.  [(accessed on 8 April 2023)].  Available online:  https://apps.who.int/iris/handle/10665/68762.</Citation></Reference><Reference><Citation>Hammon W.M., Coriell L.L., Ludwig E.H., Mcallister R.M., Greene A.E., Sather G.E., Wehrle P.F. Evaluation of Red Cross gamma globulin as a prophylactic agent for poliomyelitis. 5. Reanalysis of results based on laboratory-confirmed cases. J. Am. Med. Assoc. 1954;156:21–27. doi: 10.1001/jama.1954.02950010023009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1954.02950010023009</ArticleId><ArticleId IdType="pubmed">13183798</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker E.P., Molodecky N.A., Pons-Salort M., O’Reilly K.M., Grassly N.C. Impact of inactivated poliovirus vaccine on mucosal immunity: Implications for the polio eradication endgame. Expert. Rev. Vaccines. 2015;14:1113–1123. doi: 10.1586/14760584.2015.1052800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2015.1052800</ArticleId><ArticleId IdType="pmc">PMC4673562</ArticleId><ArticleId IdType="pubmed">26159938</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  . Manual of Laboratory Methods for Testing of Vaccines Used in the WHO Expanded Programme on Immunization. World Health Organization; Geneva, Switzerland: 1994.  [(accessed on 10 April 2023)]. Vaccine Supply and Quality Unit. Available online:  https://apps.who.int/iris/handle/10665/63576.</Citation></Reference><Reference><Citation>Zhaori G., Sun M., Faden H.S., Ogra P.L. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines. J. Infect. Dis. 1989;159:1018–1024. doi: 10.1093/infdis/159.6.1018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/159.6.1018</ArticleId><ArticleId IdType="pubmed">2470831</ArticleId></ArticleIdList></Reference><Reference><Citation>Saletti G., Çuburu N., Yang J.S., Dey A., Czerkinsky C. Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood. Nat. Protoc. 2013;8:1073–1087. doi: 10.1038/nprot.2013.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2013.058</ArticleId><ArticleId IdType="pubmed">23660756</ArticleId></ArticleIdList></Reference><Reference><Citation>Herremans T.M., Reimerink J.H., Buisman A.M., Kimman T.G., Koopmans M.P. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J. Immunol. 1999;162:5011–5018. doi: 10.4049/jimmunol.162.8.5011.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.162.8.5011</ArticleId><ArticleId IdType="pubmed">10202050</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey A., Molodecky N.A., Verma H., Sharma P., Yang J.S., Saletti G., Ahmad M., Bahl S.K., Wierzba T.F., Nandy R.K., et al. Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus. PLoS ONE. 2016;11:e0146010. doi: 10.1371/journal.pone.0146010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0146010</ArticleId><ArticleId IdType="pmc">PMC4701219</ArticleId><ArticleId IdType="pubmed">26730586</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachlin A., Patel J.C., Burns C.C., Jorba J., Tallis G., O’Leary A., Wassilak S.G.F., Vertefeuille J.F. Progress Toward Polio Eradication-Worldwide, January 2020–April 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:650–655. doi: 10.15585/mmwr.mm7119a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7119a2</ArticleId><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Hull H.F., Ward N.A., Hull B.P., Milstien J.B., de Quadros C. Paralytic poliomyelitis: Seasoned strategies, disappearing disease. Lancet. 1994;343:1331–1337. doi: 10.1016/S0140-6736(94)92472-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(94)92472-4</ArticleId><ArticleId IdType="pubmed">7910329</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinman A.R., Foege W.H., de Quadros C.A., Patriarca P.A., Orenstein W.A., Brink E.W. The case for global eradication of poliomyelitis. Bull. World Health Organ. 1987;65:835–840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2491079</ArticleId><ArticleId IdType="pubmed">3501736</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Weekly Polio Analyses WPV. 2023.  [(accessed on 9 May 2023)].  Available online:  https://https://polioeradication.org/wp-content/uploads/2023/05/weekly-polio-analyses-WPV-20230509.pdf.</Citation></Reference><Reference><Citation>Hird T.R., Grassly N.C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8:e1002599. doi: 10.1371/journal.ppat.1002599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002599</ArticleId><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>Quarleri J. Poliomyelitis is a current challenge: Long-term sequelae and circulating vaccine-derived poliovirus. Geroscience. 2023;45:707–717. doi: 10.1007/s11357-022-00672-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-022-00672-7</ArticleId><ArticleId IdType="pmc">PMC9886775</ArticleId><ArticleId IdType="pubmed">36260265</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay A.S., Garon J., Seib K., Orenstein W.A. Polio vaccination: Past, present and future. Future Microbiol. 2015;10:791–808. doi: 10.2217/fmb.15.19.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.15.19</ArticleId><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H., Deshpande J., Singh A.P., Sreevatsava M., Malankar P., et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: A randomised, double-blind, controlled trial. Lancet. 2010;376:1682–1688. doi: 10.1016/S0140-6736(10)61230-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61230-5</ArticleId><ArticleId IdType="pubmed">20980048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehndiratta M.M., Mehndiratta P., Pande R. Poliomyelitis: Historical facts, epidemiology, and current challenges in eradication. Neurohospitalist. 2014;4:223–229. doi: 10.1177/1941874414533352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1941874414533352</ArticleId><ArticleId IdType="pmc">PMC4212416</ArticleId><ArticleId IdType="pubmed">25360208</ArticleId></ArticleIdList></Reference><Reference><Citation>Estívariz C.F., Pallansch M.A., Anand A., Wassilak S.G., Sutter R.W., Wenger J.D., Orenstein W.A. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr. Opin. Virol. 2013;3:309–315. doi: 10.1016/j.coviro.2013.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2013.05.007</ArticleId><ArticleId IdType="pmc">PMC10395005</ArticleId><ArticleId IdType="pubmed">23759252</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuba IPV Study Collaborative Group Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N. Engl. J. Med. 2007;356:1536–1544. doi: 10.1056/NEJMoa054960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa054960</ArticleId><ArticleId IdType="pubmed">17429085</ArticleId></ArticleIdList></Reference><Reference><Citation>Laassri M., Lottenbach K., Belshe R., Wolff M., Rennels M., Plotkin S., Chumakov K. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J. Infect. Dis. 2005;192:2092–2098. doi: 10.1086/498172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/498172</ArticleId><ArticleId IdType="pubmed">16288372</ArticleId></ArticleIdList></Reference><Reference><Citation>Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., Bernier R.H. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. J. Infect. Dis. 1991;163:1–6. doi: 10.1093/infdis/163.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/163.1.1</ArticleId><ArticleId IdType="pubmed">1845806</ArticleId></ArticleIdList></Reference><Reference><Citation>Henry J.L., Jaikaran E.S., Davies J.R., Tomlinson A.J., Mason P.J., Barnes J.M., Beale A.J. A study of poliovaccination in infancy: Excretion following challenge with live virus by children given killed or living poliovaccine. J. Hyg. 1966;64:105–120. doi: 10.1017/S0022172400040389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0022172400040389</ArticleId><ArticleId IdType="pmc">PMC2134687</ArticleId><ArticleId IdType="pubmed">5219018</ArticleId></ArticleIdList></Reference><Reference><Citation>Murdin A.D., Barreto L., Plotkin S. Inactivated poliovirus vaccine: Past and present experience. Vaccine. 1996;14:735–746. doi: 10.1016/0264-410X(95)00211-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0264-410X(95)00211-I</ArticleId><ArticleId IdType="pubmed">8817819</ArticleId></ArticleIdList></Reference><Reference><Citation>Anis E., Kopel E., Singer S.R., Kaliner E., Moerman L., Moran-Gilad J., Sofer D., Manor Y., Shulman L.M., Mendelson E., et al. Insidious reintroduction of wild poliovirus into Israel, 2013. Euro. Surveill. 2013;18:20586. doi: 10.2807/1560-7917.ES2013.18.38.20586.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES2013.18.38.20586</ArticleId><ArticleId IdType="pubmed">24084337</ArticleId></ArticleIdList></Reference><Reference><Citation>John J., Giri S., Karthikeyan A.S., Iturriza-Gomara M., Muliyil J., Abraham A., Grassly N.C., Kang G. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: An open-label, randomised controlled trial. Lancet. 2014;384:1505–1512. doi: 10.1016/S0140-6736(14)60934-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60934-X</ArticleId><ArticleId IdType="pubmed">25018120</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari H., Deshpande J.M., Sutter R.W., Bahl S., Verma H., Ahmad M., Kunwar A., Vishwakarma R., Agarwal A., Jain S., et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science. 2014;345:922–925. doi: 10.1126/science.1255006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1255006</ArticleId><ArticleId IdType="pmc">PMC10389671</ArticleId><ArticleId IdType="pubmed">25146288</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciapponi A., Bardach A., Rey Ares L., Glujovsky D., Cafferata M.L., Cesaroni S., Bhatti A. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis. Cochrane Database Syst. Rev. 2019;12:CD011260. doi: 10.1002/14651858.CD011260.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD011260.pub2</ArticleId><ArticleId IdType="pmc">PMC6953375</ArticleId><ArticleId IdType="pubmed">31801180</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter R.W., Prevots D.R., Cochi S.L. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States. Pediatr. Clin. N. Am. 2000;47:287–308. doi: 10.1016/S0031-3955(05)70208-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0031-3955(05)70208-X</ArticleId><ArticleId IdType="pubmed">10761505</ArticleId></ArticleIdList></Reference><Reference><Citation>Korotkova E.A., Gmyl A.P., Yakovenko M.L., Ivanova O.E., Eremeeva T.P., Kozlovskaya L.I., Shakaryan A.K., Lipskaya G.Y., Parshina I.L., Loginovskikh N.V., et al. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus. J. Virol. 2016;90:5978–5988. doi: 10.1128/JVI.00277-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00277-16</ArticleId><ArticleId IdType="pmc">PMC4907227</ArticleId><ArticleId IdType="pubmed">27099315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuma J.N., Wilkinson A.L., Diop O.M., Jorba J., Gardner T., Snider C.J., Anand A., Ahmed J. Surveillance to Track Progress Toward Polio Eradication-Worldwide, 2019–2020. MMWR Morb. Mortal. Wkly. Rep. 2021;70:667–673. doi: 10.15585/mmwr.mm7018a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7018a2</ArticleId><ArticleId IdType="pmc">PMC9368747</ArticleId><ArticleId IdType="pubmed">33956779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochi S.L., Pallansch M.A. The Long and Winding Road to Eradicate Vaccine-Related Polioviruses. J. Infect. Dis. 2021;223:7–9. doi: 10.1093/infdis/jiaa393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa393</ArticleId><ArticleId IdType="pmc">PMC10546420</ArticleId><ArticleId IdType="pubmed">32621744</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern A., Yeh M.T., Zinger T., Smith M., Wright C., Ling G., Nielsen R., Macadam A., Andino R. The Evolutionary Pathway to Virulence of an RNA. Virus. Cell. 2017;169:35–46.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5787669</ArticleId><ArticleId IdType="pubmed">28340348</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen D., Pons-Salort M., Shaw A.G., Grassly N.C. The role of genetic sequencing and analysis in the polio eradication programme. Virus Evol. 2020;6:veaa040. doi: 10.1093/ve/veaa040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veaa040</ArticleId><ArticleId IdType="pmc">PMC7409915</ArticleId><ArticleId IdType="pubmed">32782825</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H.M., Zheng D.P., Zhang L.B., Oberste M.S., Kew O.M., Pallansch M.A. Serial recombination during circulation of type 1 wild-vaccine recombinant polioviruses in China. J. Virol. 2003;77:10994–11005. doi: 10.1128/JVI.77.20.10994-11005.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.20.10994-11005.2003</ArticleId><ArticleId IdType="pmc">PMC225006</ArticleId><ArticleId IdType="pubmed">14512548</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Diop O.M., Sutter R.W., Kew O.M. Vaccine-derived polioviruses. J. Infect. Dis. 2014;210:S283–S293. doi: 10.1093/infdis/jiu295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu295</ArticleId><ArticleId IdType="pubmed">25316847</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G., Diop O.M., Humayun A., Shahmahmoodi S., El-Sayed Z.A., Triki H., Rey G., Avagyan T., Grabovac V., Jorba J., et al. Update on Immunodeficiency-Associated Vaccine-Derived Polioviruses-Worldwide, July 2018–December 2019. MMWR Morb. Mortal. Wkly. Rep. 2020;69:913–917. doi: 10.15585/mmwr.mm6928a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6928a4</ArticleId><ArticleId IdType="pmc">PMC7366852</ArticleId><ArticleId IdType="pubmed">32673297</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns C.C., Shaw J., Jorba J., Bukbuk D., Adu F., Gumede N., Pate M.A., Abanida E.A., Gasasira A., Iber J., et al. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J. Virol. 2013;87:4907–4922. doi: 10.1128/JVI.02954-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02954-12</ArticleId><ArticleId IdType="pmc">PMC3624331</ArticleId><ArticleId IdType="pubmed">23408630</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.F., Naguib T., Yang S.J., Nasr E., Jorba J., Ahmed N., Campagnoli R., van der Avoort H., Shimizu H., Yoneyama T., et al. Circulation of endemic type 2 vaccine-derived poliovirus in Egypt from 1983 to 1993. J. Virol. 2003;77:8366–8377. doi: 10.1128/JVI.77.15.8366-8377.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.15.8366-8377.2003</ArticleId><ArticleId IdType="pmc">PMC165252</ArticleId><ArticleId IdType="pubmed">12857906</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitamura K., Shimizu H. The Molecular Evolution of Type 2 Vaccine-Derived Polioviruses in Individuals with Primary Immunodeficiency Diseases. Viruses. 2021;13:1407. doi: 10.3390/v13071407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13071407</ArticleId><ArticleId IdType="pmc">PMC8310373</ArticleId><ArticleId IdType="pubmed">34372613</ArticleId></ArticleIdList></Reference><Reference><Citation>Delpeyroux F., Colbère-Garapin F., Razafindratsimandresy R., Sadeuh-Mba S., Joffret M.L., Rousset D., Blondel B. Éradication de la poliomyélite et émergence de poliovirus pathogènes dérivés du vaccin-De Madagascar au Cameroun [Eradication of poliomyelitis and emergence of pathogenic vaccine-derived polioviruses: From Madagascar to Cameroon] Med. Sci. 2013;29:1034–1041.</Citation><ArticleIdList><ArticleId IdType="pubmed">24280508</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O., Morris-Glasgow V., Landaverde M., Burns C., Shaw J., Garib Z., André J., Blackman E., Freeman C.J., Jorba J., et al. Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science. 2002;296:356–359. doi: 10.1126/science.1068284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1068284</ArticleId><ArticleId IdType="pubmed">11896235</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousset D., Rakoto-Andrianarivelo M., Razafindratsimandresy R., Randriamanalina B., Guillot S., Balanant J., Mauclère P., Delpeyroux F. Recombinant vaccine-derived poliovirus in Madagascar. Emerg. Infect. Dis. 2003;9:885–887. doi: 10.3201/eid0907.020692.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid0907.020692</ArticleId><ArticleId IdType="pmc">PMC3023450</ArticleId><ArticleId IdType="pubmed">12899139</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu H., Thorley B., Paladin F.J., Brussen K.A., Stambos V., Yuen L., Utama A., Tano Y., Arita M., Yoshida H., et al. Circulation of type 1 vaccine-derived poliovirus in the Philippines in 2001. J. Virol. 2004;78:13512–13521. doi: 10.1128/JVI.78.24.13512-13521.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.24.13512-13521.2004</ArticleId><ArticleId IdType="pmc">PMC533948</ArticleId><ArticleId IdType="pubmed">15564462</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Vaccine-derived polioviruses—Update. Wkly. Epidemiol. Rec. 2006;81:398–404. (In English, French)</Citation><ArticleIdList><ArticleId IdType="pubmed">17066552</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Global update on vaccine-derived polioviruses, January 2006–August 2007. Wkly. Epidemiol. Rec. 2007;82:337–343.</Citation><ArticleIdList><ArticleId IdType="pubmed">17902237</ArticleId></ArticleIdList></Reference><Reference><Citation>Adu F., Iber J., Bukbuk D., Gumede N., Yang S.J., Jorba J., Campagnoli R., Sule W.F., Yang C.F., Burns C., et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. Virus. Res. 2007;127:17–25. doi: 10.1016/j.virusres.2007.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2007.03.009</ArticleId><ArticleId IdType="pubmed">17449127</ArticleId></ArticleIdList></Reference><Reference><Citation>Wassilak S., Pate M.A., Wannemuehler K., Jenks J., Burns C., Chenoweth P., Abanida E.A., Adu F., Baba M., Gasasira A., et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: Emergence and widespread circulation in an underimmunized population. J. Infect. Dis. 2011;203:898–909. doi: 10.1093/infdis/jiq140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiq140</ArticleId><ArticleId IdType="pmc">PMC3068031</ArticleId><ArticleId IdType="pubmed">21402542</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkins H.E., Aylward R.B., Gasasira A., Donnelly C.A., Mwanza M., Corander J., Garnier S., Chauvin C., Abanida E., Pate M.A., et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N. Engl. J. Med. 2010;362:2360–2369. doi: 10.1056/NEJMoa0910074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0910074</ArticleId><ArticleId IdType="pubmed">20573924</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC) Progress toward poliomyelitis eradication-Nigeria, January 2009–June 2010. MMWR Morb. Mortal. Wkly. Rep. 2010;59:802–807.</Citation><ArticleIdList><ArticleId IdType="pubmed">20613703</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Zhu S.L., Yoshida H., Yoneyama T., Miyamura T., Shimizu H. A Sabin 3-derived poliovirus recombinant contained a sequence homologous with indigenous human enterovirus species C in the viral polymerase coding region. J. Virol. 2005;79:12650–12657. doi: 10.1128/JVI.79.20.12650-12657.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.20.12650-12657.2005</ArticleId><ArticleId IdType="pmc">PMC1235834</ArticleId><ArticleId IdType="pubmed">16188967</ArticleId></ArticleIdList></Reference><Reference><Citation>Rakoto-Andrianarivelo M., Gumede N., Jegouic S., Balanant J., Andriamamonjy S.N., Rabemanantsoa S., Birmingham M., Randriamanalina B., Nkolomoni L., Venter M., et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. J. Infect. Dis. 2008;197:1427–1435. doi: 10.1086/587694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/587694</ArticleId><ArticleId IdType="pubmed">18419577</ArticleId></ArticleIdList></Reference><Reference><Citation>Estívariz C.F., Watkins M.A., Handoko D., Rusipah R., Deshpande J., Rana B.J., Irawan E., Widhiastuti D., Pallansch M.A., Thapa A., et al. A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005. J. Infect. Dis. 2008;197:347–354. doi: 10.1086/525049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/525049</ArticleId><ArticleId IdType="pubmed">18199031</ArticleId></ArticleIdList></Reference><Reference><Citation>Combelas N., Holmblat B., Joffret M.L., Colbère-Garapin F., Delpeyroux F. Recombination between poliovirus and coxsackie A viruses of species C: A model of viral genetic plasticity and emergence. Viruses. 2011;3:1460–1484. doi: 10.3390/v3081460.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v3081460</ArticleId><ArticleId IdType="pmc">PMC3185806</ArticleId><ArticleId IdType="pubmed">21994791</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Weekly-Polio-Analyses-cVDPV-20230425. 2023.  [(accessed on 9 May 2023)].  Available online:  https://polioeradication.org/wp-con.</Citation></Reference><Reference><Citation>Li L., Ivanova O., Driss N., Tiongco-Recto M., da Silva R., Shahmahmoodi S., Sazzad H.M., Mach O., Kahn A.L., Sutter R.W. Poliovirus excretion among persons with primary immune deficiency disorders: Summary of a seven-country study series. J. Infect. Dis. 2014;210:S368–S372. doi: 10.1093/infdis/jiu065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu065</ArticleId><ArticleId IdType="pubmed">25316857</ArticleId></ArticleIdList></Reference><Reference><Citation>Macklin G., Liao Y., Takane M., Dooling K., Gilmour S., Mach O., Kew O.M., Sutter R.W., iVDPV Working Group Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry. Front. Immunol. 2017;25:1103. doi: 10.3389/fimmu.2017.01103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01103</ArticleId><ArticleId IdType="pmc">PMC5622164</ArticleId><ArticleId IdType="pubmed">28993765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kew O.M., Sutter R.W., Nottay B.K., McDonough M.J., Prevots D.R., Quick L., Pallansch M.A. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 1998;36:2893–2899. doi: 10.1128/JCM.36.10.2893-2899.1998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.36.10.2893-2899.1998</ArticleId><ArticleId IdType="pmc">PMC105084</ArticleId><ArticleId IdType="pubmed">9738040</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttinelli G., Donati V., Fiore S., Marturano J., Plebani A., Balestri P., Soresina A.R., Vivarelli R., Delpeyroux F., Martin J., et al. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. J. Gen. Virol. 2003;84:1215–1221. doi: 10.1099/vir.0.18974-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.18974-0</ArticleId><ArticleId IdType="pubmed">12692287</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao N., Liu Y., Xu J.W., Wang Q., Yin Z.D., Wen N., Yang H., Rodewald L.E., Zhang Z.Y. Detection of a Highly Divergent Type 3 Vaccine-Derived Poliovirus in a Child with a Severe Primary Immunodeficiency Disorder-Chongqing, China, 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:1148–1150. doi: 10.15585/mmwr.mm7136a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7136a2</ArticleId><ArticleId IdType="pmc">PMC9470223</ArticleId><ArticleId IdType="pubmed">36074738</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorba J., Diop O.M., Iber J., Henderson E., Zhao K., Sutter R.W., Wassilak S.G.F., Burns C.C. Update on Vaccine-Derived Polioviruses-Worldwide, January 2017–June 2018. MMWR Morb. Mortal. Wkly. Rep. 2018;67:1189–1194. doi: 10.15585/mmwr.mm6742a5.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6742a5</ArticleId><ArticleId IdType="pmc">PMC6290814</ArticleId><ArticleId IdType="pubmed">30359342</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Polio Eradication Strategy 2022–2026: Delivering on a Promise. World Health Organization; Geneva, Switzerland: 2021.</Citation></Reference><Reference><Citation>Modlin J.F., Bandyopadhyay A.S., Sutter R. Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication. J. Infect. Dis. 2021;224:S398–S404. doi: 10.1093/infdis/jiaa622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa622</ArticleId><ArticleId IdType="pmc">PMC8482017</ArticleId><ArticleId IdType="pubmed">34590135</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton E.B., Lawson L.B., Freytag L.C., Clements J.D. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin. Vaccine Immunol. 2011;18:546–551. doi: 10.1128/CVI.00538-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00538-10</ArticleId><ArticleId IdType="pmc">PMC3122563</ArticleId><ArticleId IdType="pubmed">21288994</ArticleId></ArticleIdList></Reference><Reference><Citation>Clements J.D., Norton E.B. The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT. mSphere. 2018;3:e00215–e00218. doi: 10.1128/mSphere.00215-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00215-18</ArticleId><ArticleId IdType="pmc">PMC6060342</ArticleId><ArticleId IdType="pubmed">30045966</ArticleId></ArticleIdList></Reference><Reference><Citation>Norton E.B., Bauer D.L., Weldon W.C., Oberste M.S., Lawson L.B., Clements J.D. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015;33:1909–1915. doi: 10.1016/j.vaccine.2015.02.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.02.069</ArticleId><ArticleId IdType="pubmed">25765967</ArticleId></ArticleIdList></Reference><Reference><Citation>White J.A., Blum J.S., Hosken N.A., Marshak J.O., Duncan L., Zhu C., Norton E.B., Clements J.D., Koelle D.M., Chen D., et al. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Hum. Vaccin Immunother. 2014;10:3611–3621. doi: 10.4161/hv.32253.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.32253</ArticleId><ArticleId IdType="pmc">PMC4514067</ArticleId><ArticleId IdType="pubmed">25483682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T., Gutiérrez R.L., Maciel M., Poole S., Testa K.J., Trop S., Duplessis C., Lane A., Riddle M.S., Hamer M., et al. Safety and immunogenicity of intramuscularly administered CS6 subunit vaccine with a modified heat-labile enterotoxin from enterotoxigenic Escherichia coli. Vaccine. 2021;39:5548–5556. doi: 10.1016/j.vaccine.2021.08.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.08.032</ArticleId><ArticleId IdType="pmc">PMC8461560</ArticleId><ArticleId IdType="pubmed">34419306</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein D.I., Pasetti M.F., Brady R., Buskirk A.D., Wahid R., Dickey M., Cohen M., Baughman H., El-Khorazaty J., Maier N., et al. A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization. Vaccine. 2019;37:602–611. doi: 10.1016/j.vaccine.2018.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.12.011</ArticleId><ArticleId IdType="pmc">PMC6331259</ArticleId><ArticleId IdType="pubmed">30563789</ArticleId></ArticleIdList></Reference><Reference><Citation>Svennerholm A.M., Qadri F., Lundgren A., Kaim J., Rahman Bhuiyan T., Akhtar M., Maier N., Louis Bourgeois A., Walker R.I. Induction of mucosal and systemic immune responses against the common O78 antigen of an oral inactivated ETEC vaccine in Bangladeshi children and infants. Vaccine. 2022;40:380–389. doi: 10.1016/j.vaccine.2021.10.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.10.056</ArticleId><ArticleId IdType="pubmed">34772542</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayasu H., Sein C., Chang Blanc D., Gonzalez A.R., Zehrung D., Jarrahian C., Macklin G., Sutter R.W. Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization. J. Infect. Dis. 2017;216:S161–S167. doi: 10.1093/infdis/jix038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix038</ArticleId><ArticleId IdType="pmc">PMC5853966</ArticleId><ArticleId IdType="pubmed">28838185</ArticleId></ArticleIdList></Reference><Reference><Citation>Crothers J.W., Ross Colgate E., Cowan K.J., Dickson D.M., Walsh M., Carmolli M., Wright P.F., Norton E.B., Kirkpatrick B.D. Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with double mutant Enterotoxigenic Escherichia coli heat labile toxin (dmLT) is well-tolerated and augments a systemic immune response to all three poliovirus serotypes in a randomized placebo-controlled trial. Vaccine. 2022;40:2705–2713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9024222</ArticleId><ArticleId IdType="pubmed">35367069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessaud M. Le nouveau vaccin antipoliomyélitique oral: Un tournant décisif pour le programme d’éradication? [New oral polio vaccine: A turning point for the global polio eradication initiative?] Med. Trop. Sante Int. 2021;1:191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9283809</ArticleId><ArticleId IdType="pubmed">35891919</ArticleId></ArticleIdList></Reference><Reference><Citation>De Coster I., Leroux-Roels I., Bandyopadhyay A.S., Gast C., Withanage K., Steenackers K., De Smedt P., Aerssens A., Leroux-Roels G., Oberste M.S., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: Two clinical trials. Lancet. 2021;397:39–50. doi: 10.1016/S0140-6736(20)32541-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32541-1</ArticleId><ArticleId IdType="pmc">PMC7811203</ArticleId><ArticleId IdType="pubmed">33308429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sáez-Llorens X., Bandyopadhyay A.S., Gast C., Leon T., DeAntonio R., Jimeno J., Caballero M.I., Aguirre G., Oberste M.S., Weldon W.C., et al. Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in children and infants: Two clinical trials. Lancet. 2021;397:27–38. doi: 10.1016/S0140-6736(20)32540-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32540-X</ArticleId><ArticleId IdType="pmc">PMC7811205</ArticleId><ArticleId IdType="pubmed">33308427</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirzoev A., Macklin G.R., Zhang Y., Mainou B.A., Sadykova U., Olsavszky V.S., Huseynov S., Ruziev M., Saidzoda F., Bobokhonova M., et al. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: A population-based study in Tajikistan in 2021. Lancet Glob. Health. 2022;10:e1807–e1814. doi: 10.1016/S2214-109X(22)00412-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00412-0</ArticleId><ArticleId IdType="pmc">PMC9681660</ArticleId><ArticleId IdType="pubmed">36400086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K., Bandyopadhyay A.S., Hoque M., Gast C., Yunus M., Jamil K.M., Mainou B.A., Konopka-Anstadt J.L., Hendley W.S., Vincent A., et al. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: A randomised, controlled, phase 2 clinical trial. Lancet. 2023;401:131–139. doi: 10.1016/S0140-6736(22)02397-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02397-2</ArticleId><ArticleId IdType="pmc">PMC9860215</ArticleId><ArticleId IdType="pubmed">36495882</ArticleId></ArticleIdList></Reference><Reference><Citation>Polioeradication.  [(accessed on 10 May 2023)].  Available online:  https://polioeradication.org/news-post/gpei-statement-on-cvdpv2-detections-in-burundi-and-democratic-republic-of-the-congo/</Citation></Reference><Reference><Citation>Yang H., Qi Q., Zhang Y., Wen N., Cao L., Liu Y., Fan C., Yan D., Zhu X., Hao L., et al. Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019–2021. JAMA Netw. Open. 2023;6:e2249710. doi: 10.1001/jamanetworkopen.2022.49710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.49710</ArticleId><ArticleId IdType="pmc">PMC9856606</ArticleId><ArticleId IdType="pubmed">36602797</ArticleId></ArticleIdList></Reference><Reference><Citation>Viktorova E.G., Khattar S.K., Kouiavskaia D., Laassri M., Zagorodnyaya T., Dragunsky E., Samal S., Chumakov K., Belov G.A. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis. J. Virol. 2018;92:e00976-18. doi: 10.1128/JVI.00976-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00976-18</ArticleId><ArticleId IdType="pmc">PMC6096817</ArticleId><ArticleId IdType="pubmed">29925653</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeyemi O.O., Nicol C., Stonehouse N.J., Rowlands D.J. Increasing Type 1 Poliovirus Capsid Stability by Thermal Selection. J. Virol. 2017;91:e01586-16. doi: 10.1128/JVI.01586-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01586-16</ArticleId><ArticleId IdType="pmc">PMC5286869</ArticleId><ArticleId IdType="pubmed">27928008</ArticleId></ArticleIdList></Reference><Reference><Citation>Ansardi D.C., Porter D.C., Morrow C.D. Coinfection with recombinant vaccinia viruses expressing poliovirus P1 and P3 proteins results in polyprotein processing and formation of empty capsid structures. J. Virol. 1991;65:2088–2092. doi: 10.1128/jvi.65.4.2088-2092.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.65.4.2088-2092.1991</ArticleId><ArticleId IdType="pmc">PMC240068</ArticleId><ArticleId IdType="pubmed">1848318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahar M.W., Porta C., Fox H., Macadam A.J., Fry E.E., Stuart D.I. Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines. 2021;6:5. doi: 10.1038/s41541-020-00267-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-020-00267-3</ArticleId><ArticleId IdType="pmc">PMC7794334</ArticleId><ArticleId IdType="pubmed">33420068</ArticleId></ArticleIdList></Reference><Reference><Citation>Bräutigam S., Snezhkov E., Bishop D.H. Formation of poliovirus-like particles by recombinant baculoviruses expressing the individual VP0, VP3, and VP1 proteins by comparison to particles derived from the expressed poliovirus polyprotein. Virology. 1993;192:512–524. doi: 10.1006/viro.1993.1067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1067</ArticleId><ArticleId IdType="pubmed">8380663</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Ma S., Huang Y., Chen F., Chen L., Ding D., Zheng Y., Li H., Xiao J., Feng J., et al. Virus-like particle vaccines for poliovirus types 1, 2, and 3 with enhanced thermostability expressed in insect cells. Vaccine. 2019;37:2340–2347. doi: 10.1016/j.vaccine.2019.03.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2019.03.031</ArticleId><ArticleId IdType="pubmed">30922699</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsian J., Fox H., Bahar M.W., Kotecha A., Fry E.E., Stuart D.I., Macadam A.J., Rowlands D.J., Lomonossoff G.P. Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine. Nat. Commun. 2017;8:245. doi: 10.1038/s41467-017-00090-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00090-w</ArticleId><ArticleId IdType="pmc">PMC5557999</ArticleId><ArticleId IdType="pubmed">28811473</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry L., Grehan K., Swanson J.J., Bahar M.W., Porta C., Fry E.E., Stuart D.I., Rowlands D.J., Stonehouse N.J. Production and Characterisation of Stabilised PV-3 Virus-like Particles Using Pichia pastoris. Viruses. 2022;14:2159. doi: 10.3390/v14102159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14102159</ArticleId><ArticleId IdType="pmc">PMC9611624</ArticleId><ArticleId IdType="pubmed">36298714</ArticleId></ArticleIdList></Reference><Reference><Citation>Hummeler K., Anderson T.F., Brown R.A. Identification of poliovirus particles of different antigenicity by specific agglutination as seen in the electron microscope. Virology. 1962;16:84–90. doi: 10.1016/0042-6822(62)90205-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(62)90205-2</ArticleId><ArticleId IdType="pubmed">14449962</ArticleId></ArticleIdList></Reference><Reference><Citation>Urakawa T., Ferguson M., Minor P.D., Cooper J., Sullivan M., Almond J.W., Bishop D.H. Synthesis of immunogenic, but non-infectious, poliovirus particles in insect cells by a baculovirus expression vector. J. Gen. Virol. 1989;70:1453–1463. doi: 10.1099/0022-1317-70-6-1453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-70-6-1453</ArticleId><ArticleId IdType="pubmed">2543785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermingham W.H., Canning B., Wilton T., Kidd M., Klapsa D., Majumdar M., Sooriyakumar K., Martin J., Huissoon A.P. Case report: Clearance of longstanding, immune-deficiency-associated, vaccine-derived polio virus infection following remdesivir therapy for chronic SARS-CoV-2 infection. Front Immunol. 2023;14:1135834. doi: 10.3389/fimmu.2023.1135834.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1135834</ArticleId><ArticleId IdType="pmc">PMC10022663</ArticleId><ArticleId IdType="pubmed">36936936</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>